Franz Hefti, co-director of the Lilly Institute for Genetic Medicine and CEO of Lilly sub Prevail

Lil­ly breaks the bank on the po­ten­tial for RNA with $700M in­vest­ment in Boston's Sea­port

In the lat­est boom across drug R&D, Big Phar­ma has dumped bil­lions in­to re­search for RNA-based ther­a­pies, bet­ting big on the fu­ture in that space. Now, Eli Lil­ly wants an even big­ger piece of the ac­tion and will plant its flag in Boston to help pave the way.

Lil­ly will dole out $700 mil­lion for a new re­search site at Boston’s Sea­port dis­trict as part of the com­pa­ny’s broad­er push in­to RNA med­i­cines, the In­di­anapo­lis-based drug­mak­er said Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.